Headwaters Capital sees deep value in Bio-Techne as academic cuts weigh on shares. Learn why this life sciences leader could ...

Hims & Hers is a top telehealth stock with strong revenue growth, innovative offerings, and long-term potential. Click here ...

Q2 2025 Earnings Call Transcript August 7, 2025 Operator: Good day, and thank you for standing by. Welcome to the Arcutis ...

Overview of Cell Isolation MarketThe global Cell Isolation Market is valued at USD 15.6 Billion in 2024 and is projected to reach a value of USD 60.56 Billion by 2035 at a CAGR (Compound Annual Growth ...

A collection of articles, podcasts & tweets from around the web to keep you in touch with the Commanders, the NFC East, the NFL and sports in general, and a sprinkling of other stuff ...

KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on ...

Amid cost breakthroughs, regulatory approvals, and shifting consumer sentiment, the cultured meat sector is evolving from lab ...

The FDA says publishing complete response letters for medicines is an act of "radical transparency," but it is not as revolutionary as it seems.

Sarepta has defied an FDA request to halt all use of its gene therapy for Duchenne muscular dystrophy, creating an intriguing regulatory impasse.

Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basisTotal Rare Disease quarterly net revenues of ...

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative ...